

Financial news for VNDA dated on 2020-06-09: Why Vanda's Stock Is Trading Lower Today

Financial news for VNDA dated on 2020-06-09: Vanda Pharmaceuticals shares are trading lower after Citigroup downgraded the stock from Buy to Neutral and announced a price target of \$14 per share.

Financial news for VNDA dated on 2020-06-09: Citigroup Downgrades Vanda Pharmaceuticals to Neutral, Announces \$14 Price Target

Financial news for VNDA dated on 2020-05-20: Vanda Pharma Reports Federal District Court Granted Co. Motion To Dismiss False Claims Act Suit Filed Against Co.

Financial news for VNDA dated on 2020-05-20: Vanda Pharma Highlights CEO Proposal On Clinical Trial Data Sharing Coronavirus, Remdesivir

Financial news for VNDA dated on 2020-05-13: Vanda Pharmaceuticals Announces Agreement With FDA On Resubmission Of Application For HETLIOZ For The Treatment Of Patients With Smith-Magenis Syndrome

Financial news for VNDA dated on 2020-05-06: Vanda Pharmaceuticals Q1 Sales \$58.000M Beat \$56.870M Estimate

Financial news for VNDA dated on 2020-05-06: The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle

Financial news for VNDA dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for VNDA dated on 2020-04-17: 70 Biggest Movers From Yesterday

Financial news for VNDA dated on 2020-04-16: 52 Stocks Moving In Thursday's Mid-Day Session

Financial news for VNDA dated on 2020-04-16: 52 Stocks Moving In Thursday's Mid-Day Session

Financial news for VNDA dated on 2020-04-16: The Daily Biotech Pulse: FDA Nod For UroGen, Novavax Coronavirus Vaccine To Enter Clinics, Soligenix Licenses Vaccine Adjuvant

Financial news for VNDA dated on 2020-04-16: 33 Stocks Moving in Thursday's Pre-Market Session

Financial news for VNDA dated on 2020-04-15: Vanda Pharmaceuticals shares are trading higher after the company announced the enrollment of the first patient in the company's ODYSSEY trial. The company also announced the initiation of its CALYPSO program.

Financial news for VNDA dated on 2020-04-15: Vanda Pharmaceuticals Announces Initiation of "CALYPSO" to Study the Role of Genetic Variation in Coronavirus Infections in Collaboration With University of Washington Medicine

Financial news for VNDA dated on 2020-04-15: Vanda Pharma Reports Conducting ODYSSEY Trial With Northwell Health Related To Patients With Severe Coronavirus-Related Pneumonia

Financial news for VNDA dated on 2020-04-09: The Daily Biotech Pulse: FDA Nod For Pfizer, Vanda Forges Partnership For COVID-19 Drug Research, Neuronetics Pre-Announces Revenue Shortfall

Financial news for VNDA dated on 2020-04-08: Vanda Pharmaceuticals Inc. And The University of Illinois at Chicago Announce Partnership To Identify Novel Antivirals Against Coronavirus

Financial news for VNDA dated on 2020-04-02: Vanda Pharma Reports Initiation Of ODYSSEY Study For Patients With Coronavirus

Financial news for VNDA dated on 2020-03-30: Vanda Pharma Shares Tick Higher On Volume Following Trader Circulation Of Mar. 30-Dated ClinicalTrials.gov Study Record Detail For 'A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection'

Financial news for VNDA dated on 2020-03-19: The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latest Stage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection

Financial news for VNDA dated on 2020-03-18: The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates

Financial news for VNDA dated on 2020-03-17: The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment

Financial news for VNDA dated on 2020-03-16: Stocks That Hit 52-Week Lows On Monday

Financial news for VNDA dated on 2020-03-12: Benzinga's Top Upgrades, Downgrades For March 12, 2020

Financial news for VNDA dated on 2020-03-12: Citigroup Upgrades Vanda Pharmaceuticals to Buy, Announces \$14 Price Target

Financial news for VNDA dated on 2020-03-10: The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index

Financial news for VNDA dated on 2020-03-03: The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More

Financial news for VNDA dated on 2020-02-27: The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy

Financial news for VNDA dated on 2020-02-26: Stocks That Hit 52-Week Lows On Wednesday

Financial news for VNDA dated on 2020-02-26: Stifel Maintains Hold on Vanda Pharmaceuticals, Lowers Price Target to \$13

Financial news for VNDA dated on 2020-02-26: The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates

Financial news for VNDA dated on 2020-02-26: JMP Securities Maintains Market Outperform on Vanda Pharmaceuticals, Lowers Price Target to \$25

Financial news for VNDA dated on 2020-02-25: Vanda Pharmaceuticals Shares Resume Trade

Financial news for VNDA dated on 2020-02-25: Vanda Pharma Shares To Resume Trade At 4:40 p.m. EST

Financial news for VNDA dated on 2020-02-25: Vanda Pharma Shares To Resume Trade At 4:40 p.m. EST

Financial news for VNDA dated on 2020-02-25: Vanda Announces Results From EPIONE Study; Tradipitant Antipruritic Effects Not Seen In Moderate Or Severe Atopic Dermatitis And The Study Did Not Meet Its Primary Endpoint

Financial news for VNDA dated on 2020-02-25: Vanda Pharma Sees FY20 Sales \$240M-\$260M vs \$274.6M Estimate, Year-End Cash \$320M+

Financial news for VNDA dated on 2020-02-25: Vanda Pharmaceuticals Q4 EPS \$0.08 Misses \$0.11 Estimate, Sales \$60.93M Beat \$59.57M Estimate

Financial news for VNDA dated on 2020-02-25: Vanda Shares Halted News Pending

Financial news for VNDA dated on 2020-02-25: The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes \$1.6B Opioid Settlement

Financial news for VNDA dated on 2020-02-23: The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace

Financial news for VNDA dated on 2020-01-21: Vanda Pharmaceuticals Option Alert: Mar 20 \$16 Calls at the Ask: 1000 @ \$1.101 vs 230 OI; Earnings 2/12 After Close [est] Ref=\$15.1

Financial news for VNDA dated on 2020-01-13: Vanda Pharmaceuticals Wins U.S. Supreme Court Patent Ruling On Fanapt; Order By U.S. Supreme Court Ensures That '610 Patent Will Remain Exclusive At Least Through November 2, 2027

Financial news for VNDA dated on 2019-12-29: Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus

Financial news for VNDA dated on 2019-11-08: 94 Biggest Movers From Yesterday

Financial news for VNDA dated on 2019-11-07: 75 Stocks Moving In Thursday's Mid-Day Session

Financial news for VNDA dated on 2019-11-07: The Daily Biotech Pulse: Obseva Sinks On

Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs

Financial news for VNDA dated on 2019-11-06: Vanda Pharma Reaffirms 2019 Net Product Sales Guidance, Says it Expects Results in the Upper Half of its Previously Given Range

Financial news for VNDA dated on 2019-11-06: Vanda Pharmaceuticals Q3 EPS \$0.23 Beats \$0.07 Estimate, Sales \$59.485M Beat \$58.32M Estimate

Financial news for VNDA dated on 2019-11-06: The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings

Financial news for VNDA dated on 2019-10-23: Vanda Pharma Offers Results Of Comparative Genomics Study Presented At American Society of Human Genetics Conference

Financial news for VNDA dated on 2019-08-28: Attention Biotech Investors: Mark Your Calendar For These September PDUFA Dates

Financial news for VNDA dated on 2019-08-19: FDA Issues Complete Response For Vanda's Hetlioz In Jet Lag Disorder

Financial news for VNDA dated on 2019-08-19: 33 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for VNDA dated on 2019-08-19: 27 Stocks Moving in Monday's Pre-Market Session

Financial news for VNDA dated on 2019-08-19: Adam Feuerstein Tweet: FDA finally realizes \$VNDA is peddling cheap melatonin as an ultra-expensive branded drug. Long overdue

Financial news for VNDA dated on 2019-08-19: Vanda Pharma Receives a Complete Response Letter from the FDA for HETLIOZ in the Treatment of Jet Lag Disorder, FDA Says Vanda's Study is of Unclear Clinical Significance

Financial news for VNDA dated on 2019-08-13: Biotech Stock On The Radar: Is Vanda A Buy Ahead Of Its PDUFA Date?

Financial news for VNDA dated on 2019-08-11: The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO

Financial news for VNDA dated on 2019-08-02: 100 Biggest Movers From Yesterday

Financial news for VNDA dated on 2019-08-01: 72 Stocks Moving In Thursday's Mid-Day Session

Financial news for VNDA dated on 2019-08-01: Citi Upgrades Vanda Pharmaceuticals to Buy, Announces \$19 Price Target

Financial news for VNDA dated on 2019-08-01: The Daily Biotech Pulse: Exelixis Signs Cancer Drug Licensing Deal, Adamis Offering, Surmodics Surges On Earnings

Financial news for VNDA dated on 2019-08-01: 28 Healthcare Stocks Moving In Wednesday's After-Market Session

Financial news for VNDA dated on 2019-07-31: Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates

Financial news for VNDA dated on 2019-07-31: The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster

Financial news for VNDA dated on 2019-07-27: The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

Financial news for VNDA dated on 2019-07-25: 10 Biggest Price Target Changes For Thursday

Financial news for VNDA dated on 2019-07-25: Stifel Nicolaus Downgrades Vanda Pharmaceuticals to Hold, Lowers Price Target to \$17

Financial news for VNDA dated on 2019-07-23: The Daily Biotech Pulse: Acadia Schizophrenia Drug Fails, Viveve Plummets, Eisai Gets Breakthrough Therapy Designation

Financial news for VNDA dated on 2019-07-22: Vanda Pharmaceuticals Reports FDA Has Identified Deficiencies That Preclude Discussion Of Labeling And Postmarketing Requirements/Commitments Of HETLIOZ At This Time

Financial news for VNDA dated on 2019-07-16: Vanda Pharma Reports Tradipitant Was

Effective In Treating Motion Sickness In Study Conducted In Pacific Ocean

Financial news for VNDA dated on 2019-06-12: The Daily Biotech Pulse: Nuvecetra Files For Expanded Label For Algovita SCS, Axovant Earnings, FDA Nod For Aratana

Financial news for VNDA dated on 2019-06-10: Vanda Pharma 8-K Shows US Dept. Of Justice Reviewed Amended Complaint, Reaffirmed Decision Not To Intervene In Qui Tam Action

Financial news for VNDA dated on 2019-06-10: '\$VNDA amended Qui Tam complaint now unsealed. Three new whistleblowers allege illegal activity at the company including a former sales manager, sales rep, and unidentified current employee. Documents now live:...' -Tweets Aurelius Value

Financial news for VNDA dated on 2019-05-01: Vanda Pharmaceuticals Q1 EPS \$(0.01) Misses \$0.07 Estimate, Sales \$47.713M Miss \$51.76M Estimate

Financial news for VNDA dated on 2019-05-01: The Daily Biotech Pulse: Nabriva Stumbles At FDA Hurdle, Gilead CFO To Retire, Eisai Ends Collaboration With Purdue

Financial news for VNDA dated on 2019-02-15: 31 Stocks Moving In Friday's Pre-Market Session

Financial news for VNDA dated on 2019-02-15: 71 Biggest Movers From Yesterday

Financial news for VNDA dated on 2019-02-14: 52 Stocks Moving In Thursday's Mid-Day Session

Financial news for VNDA dated on 2019-02-14: The Daily Biotech Pulse: Vanda Q4 Results, Inovio Debt Offering, Caladrius Diabetes Drug Flunks Mid-Stage Trial

Financial news for VNDA dated on 2019-02-13: Vanda Pharmaceuticals Sees FY19 Sales \$215M-\$225M vs \$246.66M Est.

Financial news for VNDA dated on 2019-02-13: Vanda Pharmaceuticals Q4 Adj. EPS \$0.26 May Not Compare To \$0.01 Estimate, Sales \$53.04M Beat \$51.7M Estimate

Financial news for VNDA dated on 2019-02-13: The Daily Biotech Pulse: Exelixis Q4 Results, FDA Panel Greenlights J&J's Depression Drug, MacroGenics Prices Offering

Financial news for VNDA dated on 2019-02-11: Vanda Pharma Shares Fall To Session Low, Down 4%, As Traders Circulate Word Of Short Call From Aurelius Value

Financial news for VNDA dated on 2019-02-10: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

Financial news for VNDA dated on 2019-02-07: 62 Biggest Movers From Yesterday

Financial news for VNDA dated on 2019-02-06: 48 Stocks Moving In Wednesday's Mid-Day Session

Financial news for VNDA dated on 2019-02-06: Vanda Pharmaceuticals shares are trading lower after Cantor Fitzgerald downgraded the stock from overweight to neutral.

Financial news for VNDA dated on 2019-02-06: 33 Stocks Moving In Wednesday's Pre-Market Session

Financial news for VNDA dated on 2019-02-06: The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering

Financial news for VNDA dated on 2019-02-06: Cantor Fitzgerald Downgrades Vanda Pharmaceuticals to Neutral

Financial news for VNDA dated on 2019-02-05: Vanda Pharmaceuticals Files Complaint Against FDA For Requiring Studies In Animals Without Legal Authority

Financial news for VNDA dated on 2018-12-20: Vanda Pharma Reports FDA Accepted HETLIOZ Supplemental New Drug Application For Review In Treatment Of Jet Lag Disorder

Financial news for VNDA dated on 2018-12-11: Oppenheimer Downgrades Vanda Pharmaceuticals to Perform, Announces \$29 Price Target

Financial news for VNDA dated on 2018-12-10: Vanda Pharma's HETLIOX Met 1 of 2 Primary Endpoints

Financial news for VNDA dated on 2018-12-06: JMP Securities Maintains Market Outperform on Vanda Pharmaceuticals, Raises Price Target to \$52

Financial news for VNDA dated on 2018-12-04: Benzinga's Top Upgrades, Downgrades For

December 4, 2018

Financial news for VNDA dated on 2018-12-04: Stocks Which Set New 52-Week High Yesterday, Mon., Dec. 3, 2018

Financial news for VNDA dated on 2018-12-04: The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO

Financial news for VNDA dated on 2018-12-04: Cantor Fitzgerald Upgrades Vanda Pharmaceuticals to Overweight, Announces \$43 Price Target

Financial news for VNDA dated on 2018-12-04: 56 Biggest Movers From Yesterday

Financial news for VNDA dated on 2018-12-03: 46 Stocks Moving In Monday's Mid-Day Session

Financial news for VNDA dated on 2018-12-03: Vanda Pharma shares are trading higher after the company's phase 2 study of Tradipitant met its primary endpoint and most secondary endpoints.

Financial news for VNDA dated on 2018-12-03: Vanda Pharma's Phase 2 Study for Tradipitant in Patients with Gastroparesis Met its Primary Endpoint, 'Most' Secondary Endpoints

Financial news for VNDA dated on 2018-11-09: 80 Biggest Movers From Yesterday

Financial news for VNDA dated on 2018-11-08: 65 Stocks Moving In Thursday's Mid-Day Session

Financial news for VNDA dated on 2018-11-08: Jefferies Initiates Coverage On Vanda Pharmaceuticals with Buy Rating, Announces \$26 Price Target

Financial news for VNDA dated on 2018-11-07: Vanda Pharmaceuticals Maintains FY2018 Sales Guidance of \$180.0M-200.0M vs \$192.44M Est

Financial news for VNDA dated on 2018-11-07: Vanda Pharmaceuticals Inc. Q3 EPS \$0.13 Beats \$(0.02) Estimate, Sales \$49.135M Miss \$49.44M Estimate

Financial news for VNDA dated on 2018-11-07: The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie

Financial news for VNDA dated on 2018-11-04: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for VNDA dated on 2018-11-01: Vanda Reports FDA Sent Letter To Co. Related To 1 Page Of Its Corporate Website; Says Co. Modified Content On This Page

Financial news for VNDA dated on 2018-10-31: Vanda Pharma Shares Down 2.2%; Traders Circulating Word Of Cautious Comments Related To FDA Warning Letter, Source Of Comments Is Not Clear

Financial news for VNDA dated on 2018-09-27: Stocks Which Set New 52-Week High Yesterday, September 26th

Financial news for VNDA dated on 2018-09-27: 41 Biggest Movers From Yesterday

Financial news for VNDA dated on 2018-09-26: 30 Stocks Moving In Wednesday's Mid-Day Session

Financial news for VNDA dated on 2018-09-26: The Daily Biotech Pulse: Verastem's Chinese Duvelisib Licensing Deal, Aldeyra's Positive Dry Eye Disease Drug Trial

Financial news for VNDA dated on 2018-09-26: 28 Stocks Moving In Wednesday's Pre-Market Session

Financial news for VNDA dated on 2018-09-25: UPDATE: Vanda Pharma To Replace Inogen In S&P SmallCap 600

Financial news for VNDA dated on 2018-09-25: S&P Dow Jones Indices Reports Rollins Will Join S&P 500, Inogen To Join S&P MidCap 400, Vanda, Garrett Motion To Join S&P SmallCap 600

Financial news for VNDA dated on 2018-09-20: Vanda Announces Listing Of A New HETLIOZ Patent In FDA Orange Book; Patent Was Announced On Sept 11

Financial news for VNDA dated on 2018-09-14: Stifel Nicolaus Initiates Coverage On Vanda Pharmaceuticals with Buy Rating, Announces \$30 Price Target

Financial news for VNDA dated on 2018-09-12: Vanda Pharmaceuticals Announces HETLIOZ

Driving Study Demonstrates No Impairment in Next Morning Performance

Financial news for VNDA dated on 2018-08-23: Cantor Fitzgerald Initiates Coverage On Vanda Pharmaceuticals with Neutral Rating, Announces \$26 Price Target

Financial news for VNDA dated on 2018-08-14: Vanda Pharma Wins Denial of Petition For Rehearing on Fanapt

Financial news for VNDA dated on 2018-08-09: Stocks Which Set New 52-Week High Yesterday, August 8th

Financial news for VNDA dated on 2018-08-08: Stocks Which Set New 52-Week High Yesterday, August 7th

Financial news for VNDA dated on 2018-08-08: The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict

Financial news for VNDA dated on 2018-08-03: Stocks Which Set New 52-Week High Yesterday, August 2nd

Financial news for VNDA dated on 2018-08-03: The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings

Financial news for VNDA dated on 2018-08-02: The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter

Financial news for VNDA dated on 2018-08-01: Vanda Pharma Sees FY18 HETLIOZ and Fanapt Combined Sales \$180M-\$200M

Financial news for VNDA dated on 2018-08-01: Vanda Pharmaceuticals Q2 Adj. EPS \$0.15 Beats \$(0.18) Estimate, Sales \$47.35M Beat \$47.28M Estimate

Financial news for VNDA dated on 2018-08-01: Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial

Financial news for VNDA dated on 2018-07-28: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

Financial news for VNDA dated on 2018-07-20: Stocks Which Set New 52-Week High Yesterday

Financial news for VNDA dated on 2018-07-19: Benzinga's Daily Biotech Pulse: Novartis Licenses Skin Drug, 2 Stocks To Debut

Financial news for VNDA dated on 2018-05-23: Citigroup Earlier Initiated Coverage On Vanda Pharmaceuticals with Buy Rating

Financial news for VNDA dated on 2018-05-23: Vanda Pharma Reports Results From JET Study Of HETLIOZ Which Showed Effectiveness In Treating Jet Lag Disorder In Travelers Who Flew From US To UK

Financial news for VNDA dated on 2018-05-02: Vanda Pharmaceuticals Reaffirms FY2018 Sales \$180.0M-200.0M vs \$187.40M Est

Financial news for VNDA dated on 2018-05-02: Vanda Pharmaceuticals Q1 EPS \$0.14 May Not Compare To \$(0.14) Estimate, Sales \$43.592M Beat \$42.98M Estimate

Financial news for VNDA dated on 2018-05-02: Benzinga's Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings

Financial news for VNDA dated on 2018-04-13: Vanda Wins Appeal Case on Fanapt, U.S. Court of Appeals Affirms District Court's Decision

Financial news for VNDA dated on 2018-03-26: Teva Submits an NDA to the FDA Requesting Approval to Market Generic HETLIOZ, Says 6 of Vanda Pharma's Patents Which Expire in 2034 are Unenforceable

Financial news for VNDA dated on 2018-03-16: Vanda Pharmaceuticals Shares Down 6.1% After Co. Priced 5.5M Share Common Stock Offering At \$17/Share

Financial news for VNDA dated on 2018-03-16: Vanda Pharmaceuticals Prices 5.5M Share Public Offering of Common Stock @\$17/Share

Financial news for VNDA dated on 2018-03-14: Vanda Pharmaceuticals Proposes Common Stock Offering

Financial news for VNDA dated on 2018-03-05: Vanda Pharma's HETLIOZ Demonstrates Efficacy to Treat Jet Lag Disorder in an 8 Hour Phase Advance Clinical Study

Financial news for VNDA dated on 2018-02-14: Vanda Pharma Sees FY18 Combined Sales of \$180M-\$200M

Financial news for VNDA dated on 2018-02-14: Vanda Pharma Reports Q4 Adj EPS \$0.03 May Not Compare To \$(0.12) Est., Sales \$44.276M vs \$43.45M Est.

Financial news for VNDA dated on 2018-02-09: Vanguard Group Reports 6.3% Stake In Vanda Pharmaceuticals

Financial news for VNDA dated on 2018-01-19: Seaport Global Initiates Coverage On Vanda Pharmaceuticals with Buy Rating, Announces \$20.00 Price Target

Financial news for VNDA dated on 2018-01-08: 5 Stocks To Watch For January 8, 2018

Financial news for VNDA dated on 2018-01-07: Vanda Pharmaceuticals Reports Preliminary FY17 Revenue ~\$165M vs \$164.16M Est; Preliminary FY18 Revenue \$180M-\$200M vs \$193.2M Est

Financial news for VNDA dated on 2017-12-29: 7 Notable Biotechs With Data Expected By Year's End

Financial news for VNDA dated on 2017-11-30: Oppenheimer's Top Stock Picks For December

Financial news for VNDA dated on 2017-11-10: Vanda Receives Negative Opinion for Marketing Authorization from the European Medicines Agency on Fanaptum for the Treatment of Schizophrenia

Financial news for VNDA dated on 2017-11-07: Vanda Pharmaceuticals Sees Q4 Combined Product Sales \$42M-\$48M; FY17 Combined Product Sales Cut From \$165M-\$175M to \$163M-\$169M

Financial news for VNDA dated on 2017-11-07: Vanda Pharma Reports Q3 EPS \$(0.10) vs \$(0.11) Est., Sales \$41.336M vs \$43.92M Est.

Financial news for VNDA dated on 2017-10-30: Vanda Pharma Shares Up 7% Following Price Target Increase From \$21 To \$26 By Oppenheimer, Firm Cited More Favorable Forecasts For Hetlioz

Financial news for VNDA dated on 2017-10-26: Benzinga's Option Alert Recap From October 26

Financial news for VNDA dated on 2017-10-26: Vanda Pharma Option Alert: Dec 15 \$14 Puts Sweep (22) at the Bid: 1000 @ \$0.7 vs 142 OI; Ref=\$14.475

Financial news for VNDA dated on 2017-10-18: Vanda Pharmaceuticals Reaches Pricing Agreement With German National Association Of Statutory Health Insurance Funds

Financial news for VNDA dated on 2017-10-16: 29 Top Stock Ideas For October And Beyond

Financial news for VNDA dated on 2017-09-13: Vanda Pharma Shares Were Halted Ahead Of Tadipitant News, Now Resuming Trade

Financial news for VNDA dated on 2017-09-13: Vanda Pharma Reports Tradipitant Improved Itch, Disease Severity In Patients With Atopic Dermatitis

Financial news for VNDA dated on 2017-09-01: Oppenheimer Presents New Menu Of Top Picks

Financial news for VNDA dated on 2017-08-02: Vanda Pharmaceuticals Reports EPS \$0.03 vs \$(0.28) Est., Sales \$42.1M vs \$40.31M Est.

Financial news for VNDA dated on 2017-07-21: Vanda Receives Negative Opinion for Marketing Authorization from the EMA on Fanaptum

Financial news for VNDA dated on 2017-06-29: Oppenheimer Analysts Release 28 Best Ideas List

Financial news for VNDA dated on 2017-06-19: 13G Filing Shows Armistice Capital Reporting 5.1% Stake In Vanda Pharmaceuticals

Financial news for VNDA dated on 2017-05-26: Benzinga's Top Upgrades, Downgrades For May 26, 2017

Financial news for VNDA dated on 2017-05-26: H.C. Wainwright Initiates Coverage On Vanda Pharmaceuticals with Buy Rating, Announces \$18.00 Price Target

Financial news for VNDA dated on 2017-05-02: Vanda Pharmaceuticals Reports Q1 EPS

\$ (0.17) vs \$ (0.19) Est., Sales \$37.415M vs \$38.28M Est.

Financial news for VNDA dated on 2017-04-12: Oppenheimer Initiates Coverage On Vanda Pharmaceuticals With Outperform

Financial news for VNDA dated on 2017-04-06: Your Cheat Sheet For Q1 Biotech Earnings

Financial news for VNDA dated on 2017-03-29: Vanda Pharmaceuticals to Acquire Exclusive Worldwide License from UCSF to Develop, Commercialize Portfolio of CFTR Activators and Inhibitors for \$1M Initially; Up to \$46M in Milestones

Financial news for VNDA dated on 2017-02-16: 13G Filing Shows Point72 Asset Management 5% Stake In Vanda Pharmaceuticals

Financial news for VNDA dated on 2017-02-15: Vanda Pharmaceuticals Sees FY17 Rev. \$165-\$175M vs. \$168.6M

Financial news for VNDA dated on 2017-02-15: Vanda Pharmaceuticals Reports Q4 EPS \$ (0.01) vs. \$ (0.09) Est., Rev. \$38.24M vs. \$38.39M Est.

Financial news for VNDA dated on 2017-02-08: 20 Biggest Mid-Day Gainers For Wednesday

Financial news for VNDA dated on 2017-02-08: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for VNDA dated on 2017-02-08: Vanda Pharmaceuticals Trading Up 7.3% Premarket

Financial news for VNDA dated on 2017-01-09: Vanda Pharmaceuticals Reports FY16 Prelim Rev. ~\$146M vs. Est. \$147M, FY17 Rev. \$165-\$175M vs. Est. \$183M

Financial news for VNDA dated on 2016-11-14: 13F from Paulson & Co. Shows Increased Stake in Loxo Oncology, New Stake in Monster Worldwide, Steris, Talend, Tobira Therapeutics, Reduced Stakes in Pfizer, Puma Biotech, Synergy Pharma, Vanda, Liquidated Stake in Rite Aid

Financial news for VNDA dated on 2016-11-09: Benzinga's Top Initiations

Financial news for VNDA dated on 2016-11-02: Vanda Sees FY16 Rev. \$143-\$153M vs. Est. \$147M

Financial news for VNDA dated on 2016-11-02: Vanda Pharmaceuticals Reports Q3 EPS \$ (0.01) vs. Est. \$ (0.11), Rev. \$38.48M vs. Est. \$38.05M

Financial news for VNDA dated on 2016-10-24: Vanda Pharmaceuticals Settles Fanapt Patent Litigation with Taro, Grants Taro License To Sell Generic Fanapt Beginning Nov. 2027

Financial news for VNDA dated on 2016-10-06: Vanda's Fanapt, Pipeline Getting In Rhythm With Hetlioz; Jefferies Assumes At Buy

Financial news for VNDA dated on 2016-10-06: Jefferies Assumes Vanda Pharmaceuticals at Buy

Financial news for VNDA dated on 2016-09-28: 22 Stocks Which Rallied Four Days, Then Sold Off Yesterday

Financial news for VNDA dated on 2016-09-23: The Market In 5 Minutes: Indexes Looking To Close Week Higher

Financial news for VNDA dated on 2016-09-22: Vanda Shares Spiking Higher, In Talks With Investment Banks To Hire Financial Adviser To Explore Options

Financial news for VNDA dated on 2016-08-30: USPTO Dismisses Petition For IPR Of Fanapt Patent

Financial news for VNDA dated on 2016-08-26: Vanda Pharma Spikes to High of \$15.08 on Volume

Financial news for VNDA dated on 2016-08-26: Watch These 7 Huge Call Purchases In Friday Trade

Financial news for VNDA dated on 2016-08-25: Vanda Patents Found Valid and Infringed in Fanapt ANDA Litigation

Financial news for VNDA dated on 2016-08-25: PiperJaffray Maintains Overweight on Vanda Pharmaceuticals, Raises PT to \$19.00, Positive On Upside Potential

Financial news for VNDA dated on 2016-08-25: 18 Biggest Mid-Day Gainers For Thursday



Financial news for VNDA dated on 2016-08-25: Vanda Shares Spiking Higher, Hearing Court Finds Roxane's Proposed Product Induces Infringement On Vanda's '610 Fanapt Patent

Financial news for VNDA dated on 2016-08-25: Vanda Pharma Spikes to High of \$14.30 on Volume

Financial news for VNDA dated on 2016-08-25: Option Alert: VNDA Sep16 12.0 Calls Sweep: 525 @ ASK \$1.95: 1482 traded vs 151 OI: \$13.21 Ref

Financial news for VNDA dated on 2016-08-11: Watch These 7 Huge Call Purchases In Thursday Trade

Financial news for VNDA dated on 2016-08-10: Option Alert: VNDA Nov16 13.0 Calls: 1250 @ Above Ask! \$1.50: 2500 traded vs 0 OI: \$12.30 Ref

Financial news for VNDA dated on 2016-07-27: Vanda Pharmaceuticals Reports Q2 EPS \$(0.11) vs. Est. \$(0.23), Rev. \$36.02M vs. Est. \$36.03M

Financial news for VNDA dated on 2016-06-15: A Peek Into The Markets: U.S. Stock Futures Rise; Fed Decision In Focus

Financial news for VNDA dated on 2016-06-15: Vanda Gets FDA Approval For Fanapt Marketing Exclusivity

Financial news for VNDA dated on 2016-06-15: Vanda Pharma Reports FDA Has Granted Fanapt Three Years of Marketing Exclusivity for Labeling changes Related to Maintenance Treatment of Schizophrenia

Financial news for VNDA dated on 2016-05-27: 15 Stocks Moving In Friday's Pre-Market Session

Financial news for VNDA dated on 2016-05-26: Vanda Reports FDA Approval of the Fanapt Supplemental New Drug Application for Maintenance Treatment of Schizophrenia in Adults

Financial news for VNDA dated on 2016-05-04: Vanda Pharma Reaffirms FY16 Combined Product Sales of HETLIOZ, Fanapt \$143M-\$153M vs \$148M Est.

Financial news for VNDA dated on 2016-05-04: Vanda Pharma Reports Q1 Adj. EPS \$(0.17) vs \$(0.24) Est., Sales \$33.262M vs \$32.6M Est.

Financial news for VNDA dated on 2016-04-21: Option Alert: VNDA Jan17 10.0 Calls Sweep: 644 @ ASK \$1.75: 646 traded vs 145 OI: Earnings 5/4 After Close \$9.32 Ref

Financial news for VNDA dated on 2016-04-04: Vanda Announces US District Court for the District of Delaware Scheduled Dive-day Bench Trial Beginning May 15, 2017 at Which Patent Lawsuits Would be Tried Together

Financial news for VNDA dated on 2016-02-10: Vanda Pharmaceuticals Reports Q4 EPS \$(0.23) vs. Est. \$(0.26), Rev. \$31.8M vs. Est. \$31.34M

Financial news for VNDA dated on 2016-01-11: Vanda Pharmaceuticals Sees Q4 Sales \$31.80M vs \$30.80M Est

Financial news for VNDA dated on 2016-01-11: Vanda Pharmaceuticals Sees FY2016 Sales \$143.0M-153.0M vs \$146.50M Est

Financial news for VNDA dated on 2016-01-11: Vanda Pharmaceuticals Sees FY2015 Sales \$109.90M vs \$108.90M Est

Financial news for VNDA dated on 2015-12-22: Vanda Pharma Reports EMA Has Accepted Fanaptum MAA for Treatment of Schizophrenia in Adults

Financial news for VNDA dated on 2015-12-09: Vanda Pharmaceuticals Spikes to High

Financial news for VNDA dated on 2015-11-04: Mid-Morning Market Update: Markets Mostly Flat; Time Warner Beats Q3 Views

Financial news for VNDA dated on 2015-11-03: Vanda Pharmaceuticals Reports Q3 EPS \$(0.11) vs. Est. \$(0.20), Rev. \$28.3M vs. Est. \$28.84M

Financial news for VNDA dated on 2015-10-21: Benzinga's Top Initiations

Financial news for VNDA dated on 2015-10-21: Brean Capital Initiates Coverage on Vanda Pharmaceuticals at Buy, Announces \$20.00 PT

Financial news for VNDA dated on 2015-09-23: Vanda Pharma Reports Listing of New

Fanapt Patent in FDA's Orange Book

Financial news for VNDA dated on 2015-09-15: Vanda Announces FDA Has Accepted for Review the Fanapt Supplemental New Drug Application for Maintenance Treatment of Schizophrenia in Adults

Financial news for VNDA dated on 2015-09-14: Vanda Pharmaceuticals Announces Richard Gulino As General Counsel

Financial news for VNDA dated on 2015-09-10: Vanda Announces Favorable Markman Ruling in Fanapt(r) Patent Infringement Litigation

Financial news for VNDA dated on 2015-09-08: Vanda Pharmaceuticals Announces Gian Piero Reverberi As European General Manager

Financial news for VNDA dated on 2015-07-29: Vanda Pharmaceuticals Reports Q2 EPS \$(0.13) vs. Est. \$(0.29), Rev. \$27.6M vs. Est. \$24.55M

Financial news for VNDA dated on 2015-07-07: Vanda Pharma Announces European Commission Approval For Sleep Wake Disorder in the Totally Blind

Financial news for VNDA dated on 2015-07-02: Vanda Pharma Announces Listing of New HETLIOZ Patent in FDA Orange Book

Financial news for VNDA dated on 2015-06-23: Netflix Goes 7-For-1; Vanda Pharma And FibroGen Lead Tuesday's After-Hours Movers

Financial news for VNDA dated on 2015-06-23: Vanda Shares Rally \$1+ Following News REPRIEVE Study Showed Ability of Fanapt to Prevent Relapse, Impending Relapse in Adults with Schizophrenia

Financial news for VNDA dated on 2015-06-11: Label Restrictions Sought On Vanda Pharmaceuticals' Sleep Drug

Financial news for VNDA dated on 2015-06-11: WSJ Pharamlot Blog Posts: 'FDA Mistakenly Widened the Market for a Rare Sleep Disorder Drug: Petition'

Financial news for VNDA dated on 2015-05-15: Vanda Pharmaceuticals Spikes Higher on Heavy Volume

Financial news for VNDA dated on 2015-05-06: Vanda pharma Reports Q1 EPS \$(0.24) vs. Est. \$(0.25), Rev. \$22.2M vs. Est. \$20.18M

Financial news for VNDA dated on 2015-04-24: EMA Recommends Approval of Vanda Pharmaceuticals' Tasimelteon for Non 24-Hour Sleep-Wake Disorder

Financial news for VNDA dated on 2015-04-20: Vanda Pharmaceuticals Names Tom Gibbs as Chief Commercial Officer

Financial news for VNDA dated on 2015-04-13: Vanda Reports Trial Date for Two Pending Fanapt Patent Cases as Feb. 29, 2016

Financial news for VNDA dated on 2015-04-10: Baker Bros Reduces Stake In Vanda Pharma From 10.74% To 4.2%

Financial news for VNDA dated on 2015-04-10: Vanda Announces Listing of New Fanapt Patent in FDA Orange Book

Financial news for VNDA dated on 2015-04-09: Vanda Reports Listing Of Fanapt Patent In FDA Orange Book

Financial news for VNDA dated on 2015-03-31: Option Alert: Vanda May \$11 Call; 1500 Contract Trade at Ask @\$0.65

Financial news for VNDA dated on 2015-03-09: Jefferies Initiates Coverage on Vanda Pharmaceuticals at Buy, Announces \$20.00 PT

Financial news for VNDA dated on 2015-03-04: Vanda Pharma Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis

Financial news for VNDA dated on 2015-02-21: JMP Feeling Mostly Good On 4 Drug, Healthcare Stocks

Financial news for VNDA dated on 2015-02-19: Vanda Pharma Reports Q4 EPS Loss \$0.36 Vs Est Loss \$0.20, Sales \$15.4M Vs Est \$16.15M

Financial news for VNDA dated on 2015-01-23: Option Alert: Vanda Pharmaceuticals Mar \$16 Call; 1862 Contract Trade at \$0.39; Now \$12.11

Financial news for VNDA dated on 2015-01-16: Vanda Reports Listing of New Fanapt Patent in FDA Orange Book

Financial news for VNDA dated on 2015-01-15: Option Alert: Vanda Feb \$12 Call; 1784 Contract Trade at Ask @\$1.25; Currently \$11.98

Financial news for VNDA dated on 2015-01-14: Option Alert: Vanda Mar \$13 Call; 5,008 Contracts Trade vs 4786 OI; Currently \$12.08

Financial news for VNDA dated on 2015-01-09: Option Alert: Vanda Pharmaceuticals Jan \$12 Call; 3359 Contracts Traded vs 164 OI; Currently \$12.84

Financial news for VNDA dated on 2014-12-23: These Gainers Have Elevated Short Interest

Financial news for VNDA dated on 2014-12-23: Mid-Day Gainers From December 23: NQ Mobile, Vanda Pharmaceuticals, Smith & Nephew And More

Financial news for VNDA dated on 2014-12-23: Benzinga's Volume Movers

Financial news for VNDA dated on 2014-12-23: Mid-Morning Market Update: Markets Mostly Higher; Walgreen Profit Beats Expectations

Financial news for VNDA dated on 2014-12-23: Morning Market Movers

Financial news for VNDA dated on 2014-12-23: Tuesday's #PreMarket Movers: NQ Mobile, Cytokinetics, Walgreen And More

Financial news for VNDA dated on 2014-12-23: Benzinga's Top #PreMarket Gainers

Financial news for VNDA dated on 2014-12-23: Vanda Pharmaceuticals And Novartis Settle License Dispute

Financial news for VNDA dated on 2014-12-22: UPDATE: Vanda to Acquire Rights to Phase II Clinical Compound From Novartis

Financial news for VNDA dated on 2014-12-22: Novartis to Purchase \$25M Og Vanda Common Stock

Financial news for VNDA dated on 2014-10-29: Vanda Pharma Prices 5M Shares at \$11.60/Share

Financial news for VNDA dated on 2014-10-28: Vanda Pharmaceuticals Inc. Proposes Public Offering of Common Stock

Financial news for VNDA dated on 2014-10-27: Morning Market Movers

Financial news for VNDA dated on 2014-10-27: Vanda Pharma Shares Surge 11-12% as Co. Reports Q3 EPS of \$(0.04) vs \$(0.39) Est; Revenue of \$14.80M vs \$12.20M Est

Financial news for VNDA dated on 2014-10-27: Benzinga's Top #PreMarket Gainers

Financial news for VNDA dated on 2014-10-24: Option Alert: Vanda Parma Nov \$13 Call; 1,313 Contact Trade at Ask @\$0.55; Currently \$10.77

Financial news for VNDA dated on 2014-10-14: The 3 Most Volatile Biotech Stocks

Financial news for VNDA dated on 2014-10-06: Option Alert: Vanda Pharma Oct \$11 Call; 2,000 Contract Trade at Ask @\$0.50; Currently \$10.35

Financial news for VNDA dated on 2014-08-19: The Wildest Biotech Stock Out There

Financial news for VNDA dated on 2014-08-07: Vanda Pharmaceuticals Inc. Reports Q2 EPS of \$(0.64) vs \$(0.73) Est; Revenue of \$10.90M vs \$10.0M Est

Financial news for VNDA dated on 2014-08-01: 13G Filing from James Flynn and Deerfield Mgmt on Vanda Pharma Shows Raised 6.09% Stake

Financial news for VNDA dated on 2014-07-17: 8-K from Vanda Pharma Shows Novartis is Counter-Claimant in Arbitration Proceeding, Expecting Closing or Proceeding in 12-18 Mos.

Financial news for VNDA dated on 2014-07-07: 3 Small-Cap Biotechs That Institutions Are Loving

Financial news for VNDA dated on 2014-06-16: 8-K from Vanda Pharma Shows Suit Against Roxane Labs Filed, Seeking Adjudication on Alleged Patent Infringement

Financial news for VNDA dated on 2014-06-10: Empire Asset Management Initiates

Coverage on Vanda Pharmaceuticals Inc. at Sell, Announces \$6.00 PT

Financial news for VNDA dated on 2014-06-06: Vanda Pharmaceuticals Moves Higher on Volume

Financial news for VNDA dated on 2014-06-05: Vanda Shares Jumped 29% Amid Continued Success Of Hetlioz

Financial news for VNDA dated on 2014-06-04: Mid-Day Market Movers For Wednesday, June 4, 2014

Financial news for VNDA dated on 2014-06-04: Benzinga's Volume Movers

Financial news for VNDA dated on 2014-06-04: Form 8-K from Vanda Pharma Shows Expectation for FY14 Operating Expense \$110-120M

Financial news for VNDA dated on 2014-05-08: Vanda Pharmaceuticals Inc. Reports Q1 EPS of \$(0.79) vs \$(0.30) Est; Revenue of \$9.14M vs \$8.75M Est

Financial news for VNDA dated on 2014-04-09: Vanda Pharmaceuticals Announces Availability of HETLIOZ for Non-24-Hour Sleep-Wake Disorder

Financial news for VNDA dated on 2014-03-14: Vanda Pharmaceutical Battles Back After Lower Open

Financial news for VNDA dated on 2014-02-25: Vanda Pharma 10-K Shows Co. Will Now Recognize Amoritization Expense of \$1.7M in 2014, 2015, \$1.6M in 2016

Financial news for VNDA dated on 2014-02-13: Vanda Pharmaceuticals Inc. Reports Q4 EPS of \$(0.23) vs \$(0.20) Est; Revenue of \$8.78M vs \$8.50M Est

Financial news for VNDA dated on 2014-02-03: Morning Market Losers

Financial news for VNDA dated on 2014-01-31: Vanda Pharma Says FDA Okayed HETLIOZ for Treatment of Non-24-Hour Disorder, Sees Commercially Availability in Q2 of 2014

Financial news for VNDA dated on 2014-01-16: Amended 13G from Tang Capital Partners on Vanda Pharma Shows Liquidated Position

Financial news for VNDA dated on 2014-01-08: Option Alert: Vanda Pharmaceuticals Mar \$19 Call; 6,876 Contract Trade at Bid @\$0.40; Currently \$12.21

Financial news for VNDA dated on 2013-11-27: UPDATE: Piper Jaffray Initiates Coverage on Vanda Pharmaceuticals on Expected Attractive Returns

Financial news for VNDA dated on 2013-11-27: UPDATE: Piper Jaffray Maintains Overweight On Vanda Pharmaceuticals On Hetlioz Outlook

Financial news for VNDA dated on 2013-11-19: Option Alert: Vanda Pharmaceuticals January 12 Call; 4,023 Contracts Traded vs 5 Open Interest; Currently \$12.35

Financial news for VNDA dated on 2013-11-15: Market Wrap For November 15: Janet Yellen's Post Fed Nomination Keeping Markets In The Green

Financial news for VNDA dated on 2013-11-15: Benzinga's Top #PreMarket Gainers

Financial news for VNDA dated on 2013-11-15: US Stock Futures Rise Ahead of Economic Data

Financial news for VNDA dated on 2013-11-15: UPDATE: FDA Advisory Committee Recommends Approval of HETLIOZ

Financial news for VNDA dated on 2013-11-14: Shares of Vanda Pharma Trading Up 20+% Following Resumption of Trade

Financial news for VNDA dated on 2013-11-14: FDA Panel Voting 11-0 Vanda's Tasimelteon Safety Was Adequately Addressed

Financial news for VNDA dated on 2013-11-14: FDA Panel Votes 10-0 Vanda Proved Hetlioz Efficacy

Financial news for VNDA dated on 2013-11-14: FDA Panel Says Vanda Presented Substantial Evidence of Hetlioz Efficacy

Financial news for VNDA dated on 2013-11-14: FDA Panel Soon to Begin Voting on Efficacy of Vanda's Tasimelteon

Financial news for VNDA dated on 2013-11-14: FDA Panel Votes 10-1 Vanda's Non-24 Hour Hetlioz Has Appropriate Indication

Financial news for Vnda dated on 2013-11-14: UPDATE: Vanda Pharmaceuticals Halted for FDA Advisory Committee to Review HETLIOZ NDA

Financial news for Vnda dated on 2013-11-14: Vanda Pharmaceuticals Halted, Pending News

Financial news for Vnda dated on 2013-11-12: Market Wrap For November 12: Investors Continue to Speculate on the Fed's Tapering Measures

Financial news for Vnda dated on 2013-11-12: Hearing Piper Says Anticipate Approval of Tasimelteon by January 2014

Financial news for Vnda dated on 2013-11-12: UPDATE: Vanda Pharmaceuticals Rises 94% Pre-Market Vanda Pharmaceuticals as FDA Documents Say Tasimelteon is Safe and Effective Enough to Warrant Approval

Financial news for Vnda dated on 2013-11-12: Vanda Rises 62% on Release of FDA Briefing Documents

Financial news for Vnda dated on 2013-11-04: Option Alert: Vanda Pharmaceuticals December 22 Call; 3,790 Contract Trade Between Bid and Ask @\$0.30

Financial news for Vnda dated on 2013-11-04: Option Alert: Vanda Pharmaceuticals November 11 Call; 4,840 Contract Trade at Ask @\$1.50; Currently \$7.36

Financial news for Vnda dated on 2013-10-29: Option Alert: Vanda Pharmaceuticals November \$8/\$13 Call Spread; 3,000 Spread Contracts Traded' Currently \$7.74

Financial news for Vnda dated on 2013-10-21: Lazard Capital Markets Reiterates Buy on Vanda Pharmaceuticals on Good Entry Point

Financial news for Vnda dated on 2013-10-16: Vanda Pharmaceuticals Announces FDA Advisory Committee Meeting On November 14, 2013

Financial news for Vnda dated on 2013-10-10: Adam Feuerstein Tweet: 'I had dinner last night w/ 1 of 2 buysiders who called \$ARIA short perfectly. His next best short idea is \$Vnda. FDA panel disaster Nov. 14'

Financial news for Vnda dated on 2013-10-09: Shares of Vanda Pharma Bouncing Off Session Lows Despite Concern Related to Novartis's Fanapt Winning Paragraph IV Patent Notification from FDA

Financial news for Vnda dated on 2013-10-08: Option Alert: Vanda Pharmaceuticals November 14 Call; 1,590 Contracts Traded @\$1.30; Currently \$10.18

Financial news for Vnda dated on 2013-08-27: Vanda Pharmaceuticals Spikes Higher

Financial news for Vnda dated on 2013-08-13: Vanda Shares Up Nearly 2%, Lazard Sees Odds of Positive Tasimelteon FDA Panel Vote in Nov., PDUFA in Jan. as 'Extremely High'

Financial news for Vnda dated on 2013-08-07: Vanda Files To Sell 4.68 Million Shares Of Common Stock

Financial news for Vnda dated on 2013-08-06: Vanda Pharmaceuticals Proposes Public Offering of Common Stock

Financial news for Vnda dated on 2013-08-01: Jefferies Maintains Buy on Vanda Pharmaceuticals Inc., Raises PT to \$14.00

Financial news for Vnda dated on 2013-07-31: Report Vanda Paid Regulatory Consultant \$500K -TheStreet.com

Financial news for Vnda dated on 2013-07-31: Vanda Pharmaceuticals Inc. Reports Q2 EPS of \$(0.11) vs \$(0.22) Est; Revenue of \$8.30M vs \$8.43M Est

Financial news for Vnda dated on 2013-07-30: UPDATE: Jefferies Raises PT on Vanda Pharmaceuticals Following FDA Decision

Financial news for Vnda dated on 2013-07-30: Jefferies Maintains Buy on Vanda Pharmaceuticals Inc., Raises PT to \$13.00

Financial news for Vnda dated on 2013-07-29: Vanda Announces FDA Accepts Tasimelteon NDA for Priority Review in Treatment of Non-24-Hour Disorder in the Totally Blind

Financial news for Vnda dated on 2013-06-25: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of \$100,000 Investing In Vanda Pharmaceuticals, Inc. To Contact The Firm

Financial news for Vnda dated on 2013-06-20: Jefferies Maintains Buy on Vanda Pharmaceuticals Inc., Raises PT to \$11.00

Financial news for Vnda dated on 2013-06-19: With Shares of Vanda Down 21+% Following Negative The Street Article, Lazard Tells Investors to Buy the Dip, Cites Confidence for FDA Approval by Vanda Mgmt

Financial news for Vnda dated on 2013-06-19: Afternoon Market Losers

Financial news for Vnda dated on 2013-06-19: Morning Market Losers

Financial news for Vnda dated on 2013-06-19: Benzinga's Top Pre-Market Losers

Financial news for Vnda dated on 2013-06-19: Vanda Shares Fall 15% Pre-Market on Negative Adam F Article on Tasimelteon -TheStreet

Financial news for Vnda dated on 2013-06-17: Vanda Presents Positive Data from Phase 3 Tasimelteon Study

Financial news for Vnda dated on 2013-06-11: Benzinga's Volume Movers

Financial news for Vnda dated on 2013-06-11: Stocks Hitting 52-Week Highs

Financial news for Vnda dated on 2013-06-11: Vanda Pharmaceuticals Rises 11%, Baker Bros Reported 14% Stake on Monday

Financial news for Vnda dated on 2013-06-11: Benzinga's Top Pre-Market Gainers

Financial news for Vnda dated on 2013-06-04: Vanda Pharmaceuticals Moves Higher; May be Attributed to Positive CNBC Comments

Financial news for Vnda dated on 2013-06-03: Lazard Adds Vanda Pharma to 'Fresh Money Ideas' List

Financial news for Vnda dated on 2013-05-31: A Peek Into The Market Before The Trading Starts

Financial news for Vnda dated on 2013-05-31: Vanda Announces Submits NDA to FDA for Tasimelteon for Treatment of Non-24-Hour Disorder in the Totally Blind

Financial news for Vnda dated on 2013-05-24: UPDATE: Lazard Has a Buy on Vanda with a \$17 PT

Financial news for Vnda dated on 2013-05-24: Vanda CFO Says Strength May be Attributed to Positive Lazard Note

Financial news for Vnda dated on 2013-05-17: Top Performing Industries For May 17, 2013

Financial news for Vnda dated on 2013-05-17: Morning Market Movers

Financial news for Vnda dated on 2013-05-13: Stocks Hitting 52-Week Highs

Financial news for Vnda dated on 2013-05-09: Vanda Pharmaceuticals Inc. Reports Q1 EPS of \$(0.15) vs \$(0.25) Est; Revenue of \$8.07M vs \$8.42M Est

Financial news for Vnda dated on 2013-04-29: Form 8-K Shows Vanda Reported Bristol-Myers Waived Options on Tasimelteon

Financial news for Vnda dated on 2013-04-17: Vanda Pharmaceuticals Names Dr. Paolo Baroldi CMO

Financial news for Vnda dated on 2013-03-14: Vanda Withdraws Its Marketing Authorization Application For Fanaptum In The European Union

Financial news for Vnda dated on 2013-03-06: UPDATE: Piper Jaffray Initiates Vanda Pharmaceuticals with Overweight on Tasi' Potential

Financial news for Vnda dated on 2013-03-05: Piper Jaffray Initiates Coverage on Vanda Pharmaceuticals Inc. at Overweight, Announces \$8.00 PT

Financial news for Vnda dated on 2013-02-14: UPDATE: Jefferies Upgrades Vanda Pharmaceuticals to Buy on Tasimelteon Catalyst

Financial news for Vnda dated on 2013-02-14: Jefferies Upgrades Vanda Pharmaceuticals Inc. to Buy, Raises PT to \$6.00

Financial news for Vnda dated on 2013-02-12: Vanda Pharmaceuticals Inc. Reports Q4

EPS of \$(0.23) vs \$(0.18) Est; Revenue of \$7.90M vs \$8.40M Est

Financial news for VNDA dated on 2013-02-05: Lazard Initiated Coverage on Vanda Pharma with a Buy Rating, \$11 Price Target, Neurocrine Biosciences with a Buy and \$13 PT, Repros Therapeutics with Buy, \$26 PT

Financial news for VNDA dated on 2013-01-23: A Peek Into The Market Before The Trading Starts

Financial news for VNDA dated on 2013-01-23: Vanda Announces Positive Phase III Study Results for Tasimelteon for Treatment of Non-24-Hour Disorder

Financial news for VNDA dated on 2013-01-17: Benzinga's Top Initiations

Financial news for VNDA dated on 2012-12-18: Benzinga's Small Cap Movers for Tuesday December 18, 2012

Financial news for VNDA dated on 2012-12-18: Morning Market Movers

Financial news for VNDA dated on 2012-12-18: Vanda Announces Positive Results from Tasimelteon Phase III Study

Financial news for VNDA dated on 2012-12-13: Vanda Announces Negative Opinion from CHMP on Fanaptum for the Treatment of Schizophrenia

Financial news for VNDA dated on 2012-11-08: Jefferies & Company Maintains Vanda Pharmaceuticals at Hold, Lowers PT from \$4.50 to \$3.50

Financial news for VNDA dated on 2012-10-15: Vanda Pharmaceuticals Reports Tasimelteon Restores Daily Cortisol Rhythms in Blind Patients

Financial news for VNDA dated on 2012-08-02: Vanda Pharmaceuticals Reports Q2 EPS \$-0.28 vs \$-0.27 Est; Revenues \$8.38M vs \$8.30M Est

Financial news for VNDA dated on 2012-04-16: Vanda Pharmaceuticals Acquires Rights to NK-1 Receptor Antagonist from Eli Lilly and Company

Financial news for VNDA dated on 2012-04-10: Beware of Sofia Vergara-like stocks

Financial news for VNDA dated on 2012-03-13: Benzinga's Top Downgrades

Financial news for VNDA dated on 2012-03-13: UPDATE: Jefferies Downgrades Vanda Pharmaceuticals to Hold

Financial news for VNDA dated on 2012-03-13: Jefferies & Company Downgrades Vanda Pharmaceuticals from Buy to Hold, Lowers PT from \$8.5 to \$4.5

Financial news for VNDA dated on 2012-02-14: Vanda Pharmaceuticals Reports Q4 EPS \$(0.20) vs \$(0.19) Est; Revenues \$8.40M vs \$8.20M Est

Financial news for VNDA dated on 2011-12-13: Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm for Commercialization of Fanapt in Israel

Financial news for VNDA dated on 2011-11-11: Disclosure Insight Maintains Medium Risk Rating on Vanda Pharmaceuticals

Financial news for VNDA dated on 2011-08-08: Jefferies Reiterates Buy on Vanda Pharmaceuticals, Reduces PT to \$8.50

Financial news for VNDA dated on 2011-08-08: Jefferies Lowers PT On Vanda Pharmaceuticals To \$8.50

Financial news for VNDA dated on 2011-08-04: Vanda Pharmaceuticals Reports Q2 EPS \$(0.05) vs \$(0.05) Est; Revenues \$7.4M vs \$8.07M Est

Financial news for VNDA dated on 2011-08-01: Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Biotoscana Farma S.A. for Commercialization of Fanapt in Argentina.

Financial news for VNDA dated on 2011-07-26: European Medicines Agency Accepts Vanda Pharmaceuticals Inc.'s Marketing Authorization Application For Oral Iloperidone Tablets

Financial news for VNDA dated on 2011-07-11: Vanda Pharmaceuticals Announces Exclusive License Agreement with Probiomed for Commercialization of Fanapt in Mexico

Financial news for VNDA dated on 2011-06-01: Hapoalim Securities Terminates Healthcare Coverage Including Bristol-Myers, Eli Lilly, Merck and Pfizer

Financial news for VNDA dated on 2011-06-01: Hapoalim Cutting Ocverage On Multitude Of Names

Financial news for VNDA dated on 2011-04-28: List of Seven Cheap Biotech Stocks Expected to Grow, Seeking Alpha Reports (CHTP, TLOX, HGSX, VNDA, OREX, SNTA, VICL)

Financial news for VNDA dated on 2011-04-12: Hapoalim Securities Reiterates Buy Rating, \$15 PT On VNDA

Financial news for VNDA dated on 2011-03-31: A Peek Into The Market Before The Trading Starts

Financial news for VNDA dated on 2011-03-31: Vanda Pharmaceuticals to Evaluate Tasimelteon in Major Depression

Financial news for VNDA dated on 2011-02-11: UPDATE: Jefferies Color On VNDA Q4

Financial news for VNDA dated on 2011-02-11: Jefferies Lowers PT On Vanda Pharmaceuticals To \$10

Financial news for VNDA dated on 2011-02-07: Hapoalim Securities Lowers VNDA Target To \$15 From \$16

Financial news for VNDA dated on 2011-02-04: Vanda Pharmaceuticals Falling On Disappointing Drug Sales (VNDA)

Financial news for VNDA dated on 2011-01-31: Vanda Pharmaceuticals Files to Sell \$50M of Common Stock

Financial news for VNDA dated on 2011-01-19: Hapoalim Securities Decreases VNDA Estimates

Financial news for VNDA dated on 2010-12-16: 10 Unloved Stocks to Rise Up to 120%

Financial news for VNDA dated on 2010-11-15: Hapoalim Increases Vanda PT To \$16

Financial news for VNDA dated on 2010-11-15: Vanda Pharmaceuticals Pops 7% on IRS Ruling (VNDA)

Financial news for VNDA dated on 2010-11-12: Vanda Pharmaceuticals Appoints Chief Financial Officer

Financial news for VNDA dated on 2010-11-03: Vanda Pharmaceuticals Soars On Earnings Beat (VNDA)

Financial news for VNDA dated on 2010-11-03: Hapoalim Securities Reiterates Buy Rating on Vanda Pharma (VNDA)

Financial news for VNDA dated on 2010-10-05: Vanda Pharmaceuticals Reports Prescription All Time High

Financial news for VNDA dated on 2010-08-27: Vanda's Pipeline Progresses - Analyst Blog

Financial news for VNDA dated on 2010-08-05: Hapoalim Lowers Price Target On Vanda, Reiterates Buy (VNDA)

Financial news for VNDA dated on 2010-05-28: Hapoalim Securities Reiterates Buy Rating on Vanda Pharma (VNDA)

Financial news for VNDA dated on 2010-04-29: Benzinga's Top Pre-Market Losers (OPWV, GMCR, VNDA, ASMI, ZN)

Financial news for VNDA dated on 2010-04-29: Benzinga's Top Pre-Market Losers (OPWV, GMCR, VNDA, ASMI, ZN)

Financial news for VNDA dated on 2010-04-06: Benzinga's After Hours Gainers (KEY, VANDA, NKTR)

Financial news for VNDA dated on 2010-03-21: How Will Obama-Care Play Into The Markets And ETFs?

Financial news for VNDA dated on 2010-03-11: Volume Talks Wednesday March 10: Two Option Ideas on One Hot Stock

Financial news for VNDA dated on 2010-03-10: Benzinga's Volume Movers (FACT, ITMN, VNDA, BONT, HRBN)

Financial news for VNDA dated on 2010-02-17: VNDA Misses Q4 Expectations On Novartis



## Deal Related Costs

Financial news for VNDA dated on 2009-12-09: Benzinga's Top Pre- Market Gainers (HITK, NLST, RMBS, SQNM, VNDA, AVNR)

Financial news for VNDA dated on 2009-12-09: Pre-Market Top Movers (HITK, RMBS, VNDA)

Financial news for VNDA dated on 2009-10-09: This Year's Top Percentage Gainers (DDRX, SCSS, DTG, VNDA, CAR)

Financial news for VNDA dated on 2009-08-17: Stock Watch: TTNP, VNDA, DNDN, AGEN, ONTY